Lymphoma

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

By

In a case-control study using PEDS data, researchers determined the impact of inactivity on risk for Hodgkin lymphoma and non-Hodgkin lymphoma.

Complementary and Alternative Medicine Practices of Lymphoma Survivors in South Korea

Complementary and Alternative Medicine Practices of Lymphoma Survivors in South Korea

By

A study from South Korea determined the prevalence and type of CAM practices lymphoma survivors used for various purposes including ease symptoms, augment treatment, boost immunity, and gain a sense of control.

Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies

Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies

By

A review of management approaches to Hodgkin lymphoma in Europe vs the United States/North America demonstrates that although some differences exist, worldwide studies that would enhance patient outcomes are feasible.

Advanced Age Should Not Prohibit ASCT for Lymphoma

Advanced Age Should Not Prohibit ASCT for Lymphoma

By

As supportive care improves, elderly patients may benefit from high-dose chemotherapy with autologous stem cell transplantation.

Novel β-chain-targeting approach for the treatment of lymphoma [PreClinical]

1. The β-chain constant region of the T cell receptor (TCR) was targeted to specifically eliminate a population of malignant T cells. 2. Engineered chimeric antigen receptor (CAR) T cells with specificity to the β-chain constant region successfully eradicated a significant proportion of malignant T cells in mice. Evidence Rating Level: 3 (Average) Study Rundown: []

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis

By

A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.

Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma

Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma

By

The safety of breast implants has not been confirmed despite widespread use.

Chimeric antigen receptor T-cell therapy elicits treatment response in patients with refractory B-cell lymphoma

1. Patients with refractory diffuse large B-cell or follicular lymphoma demonstrated high rates of remission when treated with anti-CD19 directed chimeric antigen receptor (CAR) T-cell therapy. 2. Serious adverse events noticed in this cohort included cytokine release syndrome and encephalopathy. Evidence Rating Level: 3 (Average) Study Rundown: Diffuse large B-cell lymphoma and follicular lymphoma comprise []

Brentuximab Vedotin and Bendamustine Proves Effective as Second-line Hodgkin Lymphoma Treatment

Brentuximab Vedotin and Bendamustine Proves Effective as Second-line Hodgkin Lymphoma Treatment

By

Patients who received the recommended phase 1 dose of brentuximab vedotin and bendamustine had an overall response of 78%.

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma

By

In this analysis, researchers measured the impact and effectiveness of supportive treatments for moderate to severe anemia in patients with lymphoma or multiple myeloma, based on patient-reported outcomes.

A Rare Case of Classical Hodgkin Lymphoma 10 Years After Liver Transplantation

A Rare Case of Classical Hodgkin Lymphoma 10 Years After Liver Transplantation

By

This case describes management of a 61-year-old male with a history of chronic liver diseases and COPD who developed a posttransplant lymphoproliferative disorder 10 years after a liver transplant.

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

By

The US FDA has granted regular approval to brentuximab vedotin (Adcetris) for pcALCL and CD30-expressing MF in adult patients who received prior systemic therapy.

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib Approved for Mantle Cell Lymphoma

Acalabrutinib is a treatment option for patients with mantle cell lymphoma who have not responded to prior treatment.

Critical Thinking Key to Effective Management of Adverse Effects in Lymphoma

Critical Thinking Key to Effective Management of Adverse Effects in Lymphoma

By

Nurses' critical thinking perspective is key to recognizing and managing adverse effects in patients with lymphoma, and staying ahead of the curve in a rapidly changing clinical setting.

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

All-Cause Mortality Improved by Advances in Radiotherapy for Hodgkin Lymphoma

By

Investigators assessed the impact of advances over time in the treatment of Hodgkin lymphoma on all-cause mortality in patients with Hodgkin lymphoma who received radiotherapy alone or with chemotherapy.

Palonosetron Prevents Delayed Nausea and Vomiting After CHOP in Non-Hodgkin Lymphoma

Palonosetron Prevents Delayed Nausea and Vomiting After CHOP in Non-Hodgkin Lymphoma

By

Palonosetron effectively prevents and manages delayed CINV in patients with non-Hodgkin lymphoma.

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

By

Study reports that patients with classic relapsed/refractory Hodgkin lymphoma who received nivolumab after ASCT experienced high rates of response regardless of previous history with brentuximab vedotin.

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

[Cancer Management and Research] This research summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development.

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

By

The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

By

An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors

By

Hodgkin lymphoma survivors are at higher risk of second cancers, and that risk is even higher in those with a first-degree relative with cancer.

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

By

Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

By

Patients who were surveyed reported that the benefits of treatment with BV outweighed its risks.

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

By

PD-1 blockade with pembrolizumab was active and induced durable responses in patients with natural killer (NK)/T-cell lymphoma failing L-asparaginase.

Hepatitis C Virus Associated With Increased Risk of Variety of Cancers

Hepatitis C Virus Associated With Increased Risk of Variety of Cancers

By

Researchers have found that hepatitis C virus infection is associated with an elevated risk for developing bile duct cancers and diffuse large B-cell lymphoma.

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

[OncoTargets and Therapy] This research examines the efficacy and safety of recombinant human endostatin in combination with CHOP regimen (ECHOP) for patients with peripheral T cell lymphoma.

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

By

Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

By

The patient's history and current blood work results indicated a dangerously high potassium level. But a meticulously handled redraw proved it false.

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

By

Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

Severe Fatigue Associated With Unemployment in Hodgkin Lymphoma Survivors

By

Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs